For the quarter ending 2025-09-30, PHAT had -$14,413K decrease in cash & cash equivalents over the period. -$14,142K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -29,973 | -170,126 |
| Depreciation and amortization | 156 | 349 |
| Stock-based compensation | 9,297 | 13,812 |
| Issuance of pik interest debt | 1,179 | 2,300 |
| Accrued interest on revenue interest financing liability | 4,799 | 15,491 |
| Amortization of debt discount | 775 | 1,430 |
| Inventory reserve | 0 | 819 |
| Other | -1,209 | -3,131 |
| Prepaid expenses and other current assets | -1,392 | -6,246 |
| Accounts receivable, net | 4,534 | 12,458 |
| Accounts payable and accrued expenses | 1,114 | 5,416 |
| Accrued interest | 10 | 43 |
| Operating right-of-use assets and lease liabilities | 66 | 66 |
| Inventory | -395 | 14,178 |
| Net cash used in operating activities | -14,115 | -147,659 |
| Cash paid for property and equipment | 27 | 115 |
| Net cash used in investing activities | -27 | -115 |
| Proceeds from issuance of common stock from exercise of stock options | 293 | 80 |
| Net proceeds from issuance of debt | 0 | 0 |
| Net proceeds from underwritten public offering | 0 | - |
| Payment of employee tax obligations related to vesting of performance stock units | -564 | - |
| Net cash (used in) provided by financing activities | -271 | 80 |
| Net decrease in cash and cash equivalents and restricted cash | -14,413 | -147,694 |
| Cash and cash equivalents at beginning of period | 300,125 | - |
| Cash and cash equivalents at end of period | 138,018 | - |
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)